Breaking News

Thermo Fisher Launches SARS-CoV-2 GlobalAccess Sequencing Program

Provides 50 units of the Genexus System at a subsidized price to support global collaborative COVID-19 research.

By: Contract Pharma

Contract Pharma Staff

To accelerate national efforts focused on mapping coronavirus transmission and epidemiological studies, Thermo Fisher Scientific has launched the SARS-CoV-2 GlobalAccess Sequencing Program for research consortia and industry groups battling the spread of the pandemic globally. Under the program, the company will provide 50 units of the Ion Torrent Genexus System at a subsidized price to support global collaborative COVID-19 research.   As countries begin to reopen, the need for real-time SARS-Co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters